| antibody–drug conjugate |
| trastuzumab emtansine |
| es-BC - HER2 negative - (neo)adjuvant (NA) 1 | |
| es-BC - HER2 positive - (neo)adjuvant (NA) 4 | |
| la/mBC - HER2 positive | |
| la/mBC - HER2 positive - (neo)adjuvant (NA) | |
| la/mBC - HER2 positive - 1st Line (L1) 5 | |
| la/mBC - HER2 positive - 2nd Line (L2) 13 | |
Comparator:
vs trastuzumab; vs trastuzumab plus endocrine therapy; vs lapatinib plus capecitabine;
Risk of bias:
low;
some concerns;
high;
NA;